O35309
PR
Gene name |
Nmi |
Protein name |
N-myc-interactor |
Names |
Nmi, N-myc and STAT interactor |
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:64685 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for O35309
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-O35309-F1 | Predicted | AlphaFoldDB |
22 variants for O35309
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs3388554381 | 31 | V>G | No | EVA | |
| rs1134237289 | 53 | Q>H | No | EVA | |
| rs27911719 | 79 | K>E | No | EVA | |
| rs27911720 | 103 | E>K | No | EVA | |
| rs3388551302 | 117 | Q>* | No | EVA | |
| rs249444833 | 117 | Q>H | No | EVA | |
| rs3388549472 | 168 | E>K | No | EVA | |
| rs3388555227 | 173 | Q>* | No | EVA | |
| rs3388549375 | 179 | E>G | No | EVA | |
| rs3388553861 | 203 | S>N | No | EVA | |
| rs578684186 | 214 | V>A | No | EVA | |
| rs235305182 | 227 | M>L | No | EVA | |
| rs33503295 | 243 | C>R | No | EVA | |
| rs3388551306 | 255 | K>Q | No | EVA | |
| rs3388552091 | 259 | L>F | No | EVA | |
| rs3388549452 | 263 | L>* | No | EVA | |
| rs33357517 | 267 | P>R | No | EVA | |
| rs242277016 | 268 | V>I | No | EVA | |
| rs3388552035 | 273 | G>A | No | EVA | |
| rs3388550985 | 288 | G>R | No | EVA | |
| rs3388552994 | 297 | S>Y | No | EVA | |
| rs240343271 | 314 | I>M | No | EVA |
No associated diseases with O35309
3 regional properties for O35309
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | Nmi/IFP 35 domain | 106 - 194 | IPR009909-1 |
| domain | Nmi/IFP 35 domain | 204 - 292 | IPR009909-2 |
| domain | Nmi/IFP 35 domain, N-terminal | 30 - 105 | IPR009938 |
Functions
6 GO annotations of cellular component
| Name | Definition |
|---|---|
| cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| cytosol | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. |
| extracellular space | That part of a multicellular organism outside the cells proper, usually taken to be outside the plasma membranes, and occupied by fluid. |
| membrane | A lipid bilayer along with all the proteins and protein complexes embedded in it an attached to it. |
| nucleoplasm | That part of the nuclear content other than the chromosomes or the nucleolus. |
| nucleus | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. |
2 GO annotations of molecular function
| Name | Definition |
|---|---|
| identical protein binding | Binding to an identical protein or proteins. |
| transcription coregulator activity | A transcription regulator activity that modulates the transcription of specific gene sets via binding to a DNA-bound DNA-binding transcription factor, either on its own or as part of a complex. Coregulators often act by altering chromatin structure and modifications. For example, one class of transcription coregulators modifies chromatin structure through covalent modification of histones. A second class remodels the conformation of chromatin in an ATP-dependent fashion. A third class modulates interactions of DNA-bound DNA-binding transcription factors with other transcription coregulators. |
16 GO annotations of biological process
| Name | Definition |
|---|---|
| interferon-gamma-mediated signaling pathway | The series of molecular signals initiated by interferon-gamma binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. Interferon gamma is the only member of the type II interferon found so far. |
| macrophage activation involved in immune response | A change in morphology and behavior of a macrophage resulting from exposure to a cytokine, chemokine, cellular ligand, or soluble factor, leading to the initiation or perpetuation of an immune response. |
| negative regulation of cell population proliferation | Any process that stops, prevents or reduces the rate or extent of cell proliferation. |
| negative regulation of innate immune response | Any process that stops, prevents, or reduces the frequency, rate or extent of the innate immune response. |
| negative regulation of interferon-alpha production | Any process that stops, prevents, or reduces the frequency, rate, or extent of interferon-alpha production. |
| negative regulation of interferon-beta production | Any process that stops, prevents, or reduces the frequency, rate, or extent of interferon-beta production. |
| negative regulation of NIK/NF-kappaB signaling | Any process that stops, prevents or reduces the frequency, rate or extent of NIK/NF-kappaB signaling. |
| negative regulation of type I interferon production | Any process that stops, prevents, or reduces the frequency, rate, or extent of type I interferon production. Type I interferons include the interferon-alpha, beta, delta, episilon, zeta, kappa, tau, and omega gene families. |
| positive regulation of inflammatory response | Any process that activates or increases the frequency, rate or extent of the inflammatory response. |
| positive regulation of innate immune response | Any process that activates or increases the frequency, rate or extent of the innate immune response, the organism's first line of defense against infection. |
| positive regulation of NIK/NF-kappaB signaling | Any process that activates or increases the frequency, rate or extent of NIK/NF-kappaB signaling. |
| positive regulation of protein K48-linked ubiquitination | Any process that activates or increases the frequency, rate or extent of protein K48-linked ubiquitination. |
| protein K48-linked ubiquitination | A protein ubiquitination process in which a polymer of ubiquitin, formed by linkages between lysine residues at position 48 of the ubiquitin monomers, is added to a protein. K48-linked ubiquitination targets the substrate protein for degradation. |
| response to virus | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a virus. |
| toll-like receptor 4 signaling pathway | The series of molecular signals initiated by a ligand binding to toll-like receptor 4. |
| transcription by RNA polymerase II | The synthesis of RNA from a DNA template by RNA polymerase II (RNAP II), originating at an RNA polymerase II promoter. Includes transcription of messenger RNA (mRNA) and certain small nuclear RNAs (snRNAs). |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MDADKDNIKQ | ACDERSAEMD | DMRGEQSMGL | VHEIMSENKE | LDEEIKKLEA | ELQSDAREFQ |
| 70 | 80 | 90 | 100 | 110 | 120 |
| IKENVPEKKL | KLTSVESPKD | GCHFSNSSCS | FQVSSQILYE | LQEGQALITF | EKEEVAQNVI |
| 130 | 140 | 150 | 160 | 170 | 180 |
| SMGNHVVQME | GTPVKVSAHP | VPLNTGVRFQ | VHVDISKMKI | NVTGIPDELS | EEQTRDKLEL |
| 190 | 200 | 210 | 220 | 230 | 240 |
| SFCKSRNGGG | EVESVDYDRK | SRSAVITFVE | TGVVDKILKK | KTYPLYMNQK | CHSVAVSPCI |
| 250 | 260 | 270 | 280 | 290 | 300 |
| ERCLEKYQVF | SAVSKKTVLL | TGLEGIPVDE | ETGEDLLNIH | FQRKNNGGGE | VEVVKCSLDQ |
| 310 | |||||
| SFAAYFKEEA | RETI |